The predictive value of immunohistochemical markers in untreated Wilms' tumour: Are they useful?

World Journal of Urology

Volumn 31, Issue 4, 2013, Pages 811-816

  Ghanem, Mazen A ^a,b   van der Kwast, Theo H ^c,e   Molenaar, W M ^b   Safan, Manal A ^c   Nijman, Rien J ^d   van Steenbrugge, Gert Jan ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b MENOUFIA UNIVERSITY   (Egypt)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Immunohistochemsitry; Prognosis; Tumour markers; Untreated; Wilms' tumour

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; MIB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE; VASCULOTROPIN A; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; DISEASE COURSE; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; MALE; METABOLISM; NEPHRECTOMY; NEPHROBLASTOMA; PREDICTIVE VALUE; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSFORMING GROWTH FACTOR ALPHA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WILMS TUMOR; WT1 PROTEINS;

EID: 84881077971     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0684-1     Document Type: Article

References (26)

1. Beckwith JB, Palmer NF (1978) Histopathology and prognosis of Wilms' tumour. Cancer 41: 1937-1948.
2. Breslow NB, Churchill G, Beckwith JB, Fernbach DJ, Otherson HB, Tefft M, D'Angio GJ (1985) Prognosis for Wilms' tumour patients with nonmetastatic disease at diagnosis: results of the Second National Wilms' Tumour Study. J Clin Oncol 3: 521-531.
3. Lemerle J, Voute PA, Tournade MF, Delemarre JF, Jereb B, Ashtrom L, Flamant R, Gerard-Marchant R (1976) Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumour: preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (SIOP). Cancer 38: 647-654.
4. Burger D, Feickert HJ, Mildenberger H (1986) Current status of nephroblastoma treatment. Malignant neoplasms in childhood. Karger, New York, pp 224-242.
5. Lemerle J, Voûte PA, Tournade MF, Rodary C, Delemarre JF, Sarrazin D, Burgers JM, Sandstedt B, Mildenberger H, Carli M, Jereb B, Moorman-Voestermans CGM (1983) Effectiveness of preoperative chemotherapy in Wilms' tumour: Results of an international Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 10: 604-609.
6. D'Angio GJ (1983) SIOP and the management of Wilms' tumour. J Clin Oncol 1: 595-596.
7. Ghanem MA, van der Kwast ThH, Den Hollander JC, Sudaryo MK, Monique HA, Noordzij MA, van den Heuvel MM, Shoukri MN, Nijman RJM, van Steenbrugge GJ (2000) Expression and prognostic value of Wilms' Tumour 1 and early growth response 1 proteins in nephroblastoma. Clin Cancer Res 6: 4265-4271.
8. Ghanem MA, van der Kwast ThH, Den Hollander JC, Sudaryo MK, Rejiv BM, van den Heuvel MM, Noordzij MA, Nijman RJM, van Steenbrugge GJ (2001) Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-α, and c-erbB-2 in nephroblastoma. Cancer 92: 3120-3129.
9. Ghanem MA, van der Kwast ThH, Den Hollander JC, Sudaryo MK, van den Heuvel MM, Noordzij MA, Nijman RJM, Soliman EH, van Steenbrugge GJ (2001) The prognostic significance of apoptosis-associated proteins Bcl-2, Bax, and Bcl-X in clinical nephroblastoma. Br J Cancer 85: 1557-1563.
10. Ghanem MA, van Steenbrugge GJ, van der Kwast ThH, Sudaryo MK, Noordzij MA, Nijman RJM (2002) Expression and prognostic value of CD44 isoforms in Nephroblastoma (Wilms' tumour). J Urol 168: 681-686.
11. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, van der Kwast ThH (2003) Expression and prognostic value of vascular endothelial growth factor (VEGF) and its receptor (Flt-1) in nephroblastom. J Clin Pathol 56: 107-113.
12. kip1 in nephroblastoma. Clin Cancer Res 10: 591-597.
13. D'Angio GJ, Breslow W, Beckwith JB, Evans A, Baum H, DeLorimer A, Fernbach D, Hrabovsky E, Jones B, Kelalis P, Othersen B, Tefft M, Thomas R (1989) Treatment of Wilms' tumour: results of the Third National Wilms' Tumour Study. Cancer 64: 349-360.
14. Vujanic GM, Sandstedt B, Harms D, Kelsey A, leuschmer I, de Kraker J (2002) Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumours of childhood. Med Paediatr Oncol 38: 79-82.
15. van Leewen EH, Postma A, Oesterhuis JW, Meiring A, Koudstaal J, Molenaar WM (1987) An analysis of histology and DNA-ploidy in primary Wilms' tumours and their metastases and a study of the morphological effects of therapy. Virchows Arch 410: 487-494.
16. Guarda LA, Ayala AG, Jaffe N, Suttow WW, Bracken RB (1984) Chemotherapy-induced histologic changes in Wilms' tumours. Pediatr Pathol 2: 197-206.
17. de Kraker J, Weitzman S, Voûte PA (1985) Preoperative strategies in the management of Wilms' tumour. Hematol Oncol Clin North Am 9: 1275-1285.
18. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP (1990) Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294.
19. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tann EM (1986) Expression of proliferating cell nuclear antigen (PCNA/Cyclin) during the cell cycle. Exp Cell Res 166: 209-219.
20. Krajewska M, Fenoglio Preiser CM, Krajewski S, Song K, Macdonald JS, Stemmermann G, Reed JC (1996) Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am J Pathol 149: 1449-1457.
21. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576.
22. Nowicki M, Ostalska-Nowicka D, Kaczmarek M, Miskowiak B, Witt M (2007) The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour). Histopathology 50: 358-364.
23. Ozluk Y, Kilicaslan I, Gulluoglu MG, Ayan I, Uysal V (2006) The prognostic significance of angiogenesis and the effect of vascular endothelial growth factor on angiogenic process in Wilms' tumour. Pathology 38: 408-414.
24. Takahashi M, Yang X, Lavery T, Furge K, Williams B, Tretiakova M, Montag A, Vogelzang N, Re G, Garvin A, Soderhall S, Kagawa S, Hazel-Martin D, Nordenskjold A, Teh B (2002) Gene expression profiling of favourable histology Wilms' tumours and its correlation with clinical features. Cancer Res 62: 6598-6605.
25. Fridman E, Pinthus JH, Kopolovic J, Ramon J, Mor O, Mor Y (2006) Expression of cyclooxygenase-2 in Wilms' tumour: immunohistochemical study using tissue microarray methodology. J Urol 176: 1747-1750.
26. Bien E, Balcerska A, Kuchta G (2007) Serum level of soluble interleukin-2 receptor alpha correlates with the clinical course and activity of Wilms' tumour and soft tissue sarcomas in children. Biomarkers 12: 203-213.